股东大会通知 证券代码：301033 证券简称：迈普医学 公告编号：2025-030 广州迈普再生医学科技股份有限公司 关于召开 2025 年第一次临时股东大会的通知公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2025 年第一次临时股东大会。 （二）股东大会的召集人：广州迈普再生医学科技股份有限公司 （以下简称"公司"、"迈普医学"）董事会。 （三）会议召开的合法、合规性：公司第三届董事会第九次会议 决议召开本次股东大会。本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的有关规定。 （四）会议召开日期和时间： 1、现场会议召开时间：2025 年 6 月 13 日（星期五）下午 14:30； 2、网络投票日期、时间： （1）通过深圳证券交易所（以下简称"深交所"）交易系统进 行网络投票的具体时间为：2025 年 6 月 13 日 9:15—9:25,9:30— 11:30 和 13:00—15:00； （2）通过深交所互联网投票系统（http://wltp.cninfo.com. ...

股份质押的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-028 广州迈普再生医学科技股份有限公司 关于公司股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）近日 接到公司股东、董事袁美福先生的函告，获悉其所持有的公司部分股 份办理了质押登记手续，具体情况如下： 注：1、上述质押股份不负担重大资产重组等业绩补偿义务； 2、本公告中的无限售条件流通股包括高管锁定股，不存在股份 冻结情形，下同； 3、公司目前总股本为 66,519,431 股（含回购股份）。 股东名 称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质 押数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 是否 为限 售股 是否 为补 充质 押 质押起 始日 质押到 期日期 质权人 质 押 用途 袁美福 否 600,00 0 20.65 0.90 否 否 2025-5 -26 至办理 解除质 押日结 束 深圳市深 担增信融 资担保有 限公司 个人 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 20% in stock price compared to the market benchmark within the next six months [20]. Core Views - The company has demonstrated sustained high growth in performance, with a reported revenue of 278 million yuan for 2024, representing a year-on-year increase of 20.6%, and a net profit of 78 million yuan, up 92.9% year-on-year [4]. - The growth is driven by the expansion of existing products and the introduction of new products, particularly in the hemostatic gauze and dural adhesive segments, which are expected to enter a rapid commercialization phase [5]. - The company has optimized its cost structure, leading to a decrease in sales expense ratio, which was 15.8% in Q1 2025, down from 20.54% for the entire year of 2024 [4]. Financial Performance Summary - For 2024, the company achieved a revenue of 278 million yuan, with a net profit of 79 million yuan, and for Q1 2025, revenue reached 73 million yuan, reflecting a 28.8% year-on-year growth [4]. - The revenue projections for 2025-2027 are estimated at 370 million yuan, 460 million yuan, and 560 million yuan, respectively, with year-on-year growth rates of 31%, 26%, and 22% [5]. - The net profit forecasts for the same period are 120 million yuan, 158 million yuan, and 201 million yuan, with growth rates of 53%, 32%, and 27% [5]. Key Financial Metrics - The company's earnings per share (EPS) are projected to be 1.81 yuan in 2025, 2.38 yuan in 2026, and 3.02 yuan in 2027 [6]. - The price-to-earnings (P/E) ratio is expected to decrease from 54.1 in 2024 to 21.2 by 2027, indicating improving valuation [6]. - The gross margin is projected to decline slightly from 79.3% in 2024 to 75.3% in 2027, while the net profit margin is expected to improve from 28.3% to 35.6% over the same period [13].

证券代码：301033 证券简称：迈普医学 公告编号：2025-027 权益分派实施公告 广州迈普再生医学科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 根据《公司法》等相关规定，上市公司回购专用账户中的股份， 不享有股东大会表决权、利润分配、公积金转增股本、认购新股和可 转换公司债券等权利。广州迈普再生医学科技股份有限公司（以下简 称"公司"）回购专用证券账户中的 352,500 股股份不参与本次权益 分派。本次实际参与现金分红的股本为 66,166,931 股，实际派发现 金分红总额 39,700,158.60 元（含税）。本次权益分派实施后除权除 息价格计算时，按公司总股本（含回购股份）折算的每 10 股现金分 红 （ 含 税 ） = 实 际 现 金 分 红 总 额 / 总 股 本 *10=39,700,158.60 元 /66,519,431 股*10=5.968204 元(保留六位小数，最后一位直接舍去， 不四舍五入)。本次权益分派实施后的除权除息价格参考价=权益分派 股权登记日收盘价-0.5968204 元/股。 公司 ...

证券代码：301033 证券简称：迈普医学 公告编号：2025-027 广州迈普再生医学科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 根据《公司法》等相关规定，上市公司回购专用账户中的股份， 不享有股东大会表决权、利润分配、公积金转增股本、认购新股和可 转换公司债券等权利。广州迈普再生医学科技股份有限公司（以下简 称"公司"）回购专用证券账户中的 352,500 股股份不参与本次权益 分派。本次实际参与现金分红的股本为 66,166,931 股，实际派发现 金分红总额 39,700,158.60 元（含税）。本次权益分派实施后除权除 息价格计算时，按公司总股本（含回购股份）折算的每 10 股现金分 红（含税）=实际现金分红总额/总股本*10=39,700,158.60 元 /66,519,431 股*10=5.968204 元(保留六位小数，最后一位直接舍去， 不四舍五入)。本次权益分派实施后的除权除息价格参考价=权益分派 股权登记日收盘价-0.5968204 元/股。 权益分派实施公告 公司2 ...

Core Viewpoint - Myp Medical (301033.SZ) is planning to acquire at least 51% of Guangzhou Yijie Medical Technology Co., Ltd. (Yijie Medical), which is expected to constitute a major asset restructuring and related party transaction [1][2] Group 1: Acquisition Details - The acquisition will make Myp Medical the controlling shareholder of Yijie Medical, which specializes in stroke treatment products and has a presence in 100 cities across 20 countries [1][2] - Myp Medical has signed a letter of intent with major parties including Zexin Medical and Yichuangxiang, with the specific transaction plan to be disclosed within 10 trading days [2] Group 2: Company Performance - Myp Medical has shown continuous growth in performance, with Q1 2025 revenue and net profit increasing by 28.84% and 61.68% year-on-year, respectively [1][5] - The company reported a revenue increase from 539.3 million to 1.24 billion from 2017 to 2020, and from 1.54 billion to 2.78 billion from 2021 to 2024, with a compound annual growth rate of approximately 17% [5] Group 3: Financial Health - As of March 2025, Myp Medical had cash reserves of 38.37 million, total assets of 816 million, and total liabilities of 88.02 million, resulting in a debt-to-asset ratio of 10.79% [3] - The company has established strong relationships with nearly 1,000 distributors and its products are available in almost 2,000 hospitals in China [4] Group 4: Market Performance - Myp Medical's stock price has seen significant growth, rising from a low of 21.97 yuan per share in February 2024 to 64.13 yuan per share as of May 21, 2024, marking an increase of nearly 200% [6]

Group 1 - Qingmu Technology plans to reduce its shareholding by up to 3%, amounting to no more than 2.776 million shares [1] - Newcap received a decision from the police to revoke the case against its actual controller, who was previously detained for insider trading [2] - Rhine Biotech's directors and executives plan to collectively reduce their holdings by up to 0.14%, totaling no more than 1.0185 million shares [3] Group 2 - Puli Tui's stock and convertible bonds will be delisted on May 22, 2025 [5] - *ST Nong Shang will have its delisting risk warning lifted and will resume trading on May 23, 2025 [7] - State Grid Information Communication plans to acquire 100% equity of Yili Technology for approximately 1.853 billion yuan [9] Group 3 - Kelun Pharmaceutical's subsidiary received drug registration approval for a new injectable product, which is the first of its kind in China [10] - Aishida plans to acquire 7% equity of its subsidiary Zhejiang Qianjiang Robot Co., Ltd. for 13.09 million yuan [11] - Hongming Co. is planning to acquire 83% equity of Shenzhen Chisu Automation Equipment Co., Ltd. for approximately 151 million yuan [12] Group 4 - JuJiao Co. plans to reduce its shareholding by up to 2.6%, totaling no more than 2.093 million shares [14] - AVIC Financial's stock will be delisted on May 27, 2025 [16] - Jingwang Electronics' major shareholders plan to reduce their holdings by up to 2.99% [17] Group 5 - Huaren Health intends to acquire stakes in three pharmaceutical chain companies for a total of 327 million yuan [18] - Huanrui Century's original shareholders are required to compensate for unfulfilled performance commitments with 116 million shares [20] - Tefa Service's shareholders plan to reduce their holdings by up to 3% [21] Group 6 - Maipu Medical is planning to acquire at least 51% of Easy Medical's equity, which will constitute a major asset restructuring [22] - *ST Jinshi will have its delisting risk warning lifted and its stock will resume trading on May 23, 2025 [22] - Guoke Micro is planning a major asset restructuring and will suspend trading [23] Group 7 - Defu Technology intends to acquire 100% equity of an overseas electronic circuit copper foil company [24] - Xince Standard's shareholder plans to reduce its holdings by up to 1% [25] - Xiouqiang Co. plans to reduce its holdings by up to 3% [27]

Market Overview - The U.S. stock market experienced a significant decline, with all three major indices posting their largest drop in a month. The Dow Jones fell by 1.91%, the Nasdaq decreased by 1.41%, and the S&P 500 dropped by 1.61% [3] - Major technology stocks also saw declines, with Tesla and Apple each dropping over 2%, while Microsoft, Amazon, and Nvidia fell more than 1%. In contrast, Google saw an increase of nearly 3% [3] Economic Indicators - The yield on the 30-year Treasury bond rose to 5.09%, while the yield on the benchmark 10-year Treasury increased by 11.5 basis points to 4.59%. The 2-year Treasury yield also rose by 4.7 basis points to 4.01%, indicating a close relationship with interest rate expectations [3] Policy Measures - A joint announcement from several Chinese financial regulatory bodies outlined 23 measures to support financing for small and micro enterprises, focusing on increasing financing supply, reducing costs, and improving efficiency [4] - The Shanghai government released a special action plan to boost consumption, emphasizing the integration of advanced technologies like AI and big data into consumer sectors [5] Corporate Actions - Guokai Micro announced plans to acquire assets through a combination of stock issuance and cash payment, focusing on semiconductor wafer foundry and customized chip manufacturing, which is expected to constitute a major asset restructuring [7] - Vanke A signed a borrowing agreement with Shenzhen Metro Group for up to 4.2 billion yuan, using up to 6 billion yuan worth of stock as collateral [8] - Myp Medical is planning to acquire at least 51% of Easy Medical, which is expected to constitute a major asset restructuring [10] - Hongming Co. is planning to purchase 83% of Shenzhen Chisu Automation Equipment for an estimated 151 million yuan, which will also constitute a major asset restructuring [12]

停牌公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-026 停牌公告 时披露停牌期间筹划事项的主要工作、事项进展、对公司的影响以及 后续安排等事项，充分提示相关事项的风险和不确定性，并承诺自披 露相关公告之日起至少 1 个月内不再筹划重大资产重组事项。 广州迈普再生医学科技股份有限公司 关于筹划发行股份及支付现金购买资产 并募集配套资金暨关联交易事项的停牌公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、停牌事由和工作安排 广州迈普再生医学科技股份有限公司（以下简称"公司"）正在 筹划发行股份购买资产及支付现金购买资产并募集配套资金事项，根 据初步研究和测算，本次交易预计构成重大资产重组，构成关联交易， 不构成重组上市。因有关事项尚存不确定性，为了维护投资者利益， 避免对公司证券交易造成重大影响，根据深圳证券交易所的相关规定， 经公司申请，公司证券（证券品种：A 股股票，证券简称：迈普医学， 证券代码：301033）自 2025 年 5 月 22 日开市起开始停牌。 公司预计在不超过 10 个交易日的时间内披露本次交易方案，即 在 ...

股东大会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-025 广州迈普再生医学科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日下午 14:30 以现场表决和网络投票相结合的方式召 开公司 2024 年年度股东大会。 1、会议召开时间：2025 年 5 月 16 日（星期五）下午 14:30 2、会议召开地点：广州市黄埔区崖鹰石路 3 号迈普医学大厦会 议室 3、会议召开方式：采取现场表决与网络投票相结合的方式。现 场会议召开时间：2025 年 5 月 16 日（星期五）。网络投票时间：通 过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 16 股东大会决议公告 日上午 9:15-9:25，9:30-11:30 和下午 13:0 ...